{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open-Label+Placebo",
    "query": {
      "intervention": "Open-Label Placebo"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1984,
    "total_pages": 199,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open-Label+Placebo&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T11:43:47.219Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00273650",
      "title": "Efficacy Study of Subcutaneous Methyl-B12 in Children With Autism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Autistic Disorder"
      ],
      "interventions": [
        {
          "name": "methylcobalamin",
          "type": "DRUG"
        },
        {
          "name": "saline placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "8 Years",
        "sex": "ALL",
        "summary": "3 Years to 8 Years"
      },
      "enrollment_count": 30,
      "start_date": "2005-07",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2019-10-09",
      "last_synced_at": "2026-09-03T11:43:47.219Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00273650"
    },
    {
      "nct_id": "NCT05499013",
      "title": "Study to Assess SLN124 in Patients With Polycythemia Vera",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Polycythemia Vera"
      ],
      "interventions": [
        {
          "name": "SLN124",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Silence Therapeutics plc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2023-01-26",
      "completion_date": "2030-03",
      "has_results": false,
      "last_update_posted_date": "2025-12-19",
      "last_synced_at": "2026-09-03T11:43:47.219Z",
      "location_count": 5,
      "location_summary": "Hammond, Louisiana • Buffalo, New York • New York, New York + 2 more",
      "locations": [
        {
          "city": "Hammond",
          "state": "Louisiana"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Huntsville",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05499013"
    },
    {
      "nct_id": "NCT06848348",
      "title": "Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chemotherapy Induced Neuropathic Pain",
        "Chemotherapy Induced Pain Neuropathy",
        "Chemotherapy Induced Pain"
      ],
      "interventions": [
        {
          "name": "Halneuron",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Halneuron (Open Label Extension)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dogwood Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2025-02-21",
      "completion_date": "2026-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-09-03T11:43:47.219Z",
      "location_count": 25,
      "location_summary": "Sheffield, Alabama • Glendale, Arizona • Phoenix, Arizona + 21 more",
      "locations": [
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fair Oaks",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06848348"
    },
    {
      "nct_id": "NCT03183024",
      "title": "Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Idiopathic Urticaria"
      ],
      "interventions": [
        {
          "name": "benralizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Jonathan A. Bernstein, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "19 Years to 70 Years"
      },
      "enrollment_count": 12,
      "start_date": "2017-09-12",
      "completion_date": "2018-11-06",
      "has_results": false,
      "last_update_posted_date": "2019-07-10",
      "last_synced_at": "2026-09-03T11:43:47.219Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03183024"
    },
    {
      "nct_id": "NCT01742208",
      "title": "Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Sotagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lexicon Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "2013-02",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2020-02-12",
      "last_synced_at": "2026-09-03T11:43:47.219Z",
      "location_count": 7,
      "location_summary": "Aurora, Colorado • Atlanta, Georgia • Baton Rouge, Louisiana + 4 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01742208"
    },
    {
      "nct_id": "NCT00538850",
      "title": "Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Fentanyl sublingual spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "INSYS Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2007-10",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2014-03-05",
      "last_synced_at": "2026-09-03T11:43:47.219Z",
      "location_count": 1,
      "location_summary": "Chandler, Arizona",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00538850"
    },
    {
      "nct_id": "NCT04166058",
      "title": "Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Irritable Bowel Syndrome With Constipation",
        "Functional Constipation"
      ],
      "interventions": [
        {
          "name": "Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers)",
          "type": "DRUG"
        },
        {
          "name": "Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Years to 18 Years"
      },
      "enrollment_count": 381,
      "start_date": "2019-11-19",
      "completion_date": "2025-06-05",
      "has_results": true,
      "last_update_posted_date": "2026-01-06",
      "last_synced_at": "2026-09-03T11:43:47.219Z",
      "location_count": 65,
      "location_summary": "Birmingham, Alabama • Foley, Alabama • Saraland, Alabama + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Foley",
          "state": "Alabama"
        },
        {
          "city": "Saraland",
          "state": "Alabama"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04166058"
    },
    {
      "nct_id": "NCT02219685",
      "title": "Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C Virus Infection"
      ],
      "interventions": [
        {
          "name": "LDV/SOF",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 40,
      "start_date": "2014-08",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2018-11-16",
      "last_synced_at": "2026-09-03T11:43:47.219Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02219685"
    },
    {
      "nct_id": "NCT05750017",
      "title": "A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Herpes Zoster",
        "Vaccine-Preventable Diseases"
      ],
      "interventions": [
        {
          "name": "Low Dose Recombinant Herpes Zoster Vaccine (LZ901)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High Dose Recombinant Herpes Zoster Vaccine (LZ901)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Beijing Luzhu Biotechnology Co., Ltd.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "50 Years to 70 Years"
      },
      "enrollment_count": 66,
      "start_date": "2023-03-23",
      "completion_date": "2024-03-15",
      "has_results": false,
      "last_update_posted_date": "2023-03-27",
      "last_synced_at": "2026-09-03T11:43:47.219Z",
      "location_count": 1,
      "location_summary": "Secaucus, New Jersey",
      "locations": [
        {
          "city": "Secaucus",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05750017"
    },
    {
      "nct_id": "NCT05556096",
      "title": "Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Generalized Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "ALXN1720",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 260,
      "start_date": "2022-11-21",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-09-03T11:43:47.219Z",
      "location_count": 23,
      "location_summary": "Orange, California • Fort Collins, Colorado • Washington D.C., District of Columbia + 20 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05556096"
    }
  ]
}